Your Molecule
Your Molecule

Virus and Viral Vector Formulation

Virus and Viral Vector Formulation

Stabilization strategies tailored to virus structure, vector type and delivery needs.

Early risk identification to design stable, patient-ready drug products

Laboratory staff

Why viral vector formulation matters

Why viral vector formulation matters

Biologic products based on viruses are among the most structurally fragile molecules in drug development. They are prone to aggregation, shear sensitivity, envelope disruption, and chemical degradation. Whether used as gene therapy vectors, oncolytic viruses, or vaccine platforms, viral therapeutics require intelligent, fine-tuned formulation to maintain potency, safety, and manufacturability.

With experience in more than 100 virus-based projects, Leukocare has built a unique formulation knowledge base spanning enveloped and non-enveloped viruses, DNA and RNA virus types, virus-like particles (VLPs), viral vector-based gene therapies, and both live-attenuated and inactivated vaccines.



Explore our full modalities hub


Biologic products based on viruses are among the most structurally fragile molecules in drug development. They are prone to aggregation, shear sensitivity, envelope disruption, and chemical degradation. Whether used as gene therapy vectors, oncolytic viruses, or vaccine platforms, viral therapeutics require intelligent, fine-tuned formulation to maintain potency, safety, and manufacturability.

With experience in more than 100 virus-based projects, Leukocare has built a unique formulation knowledge base spanning enveloped and non-enveloped viruses, DNA and RNA virus types, virus-like particles (VLPs), viral vector-based gene therapies, and both live-attenuated and inactivated vaccines.



Explore our full modalities hub


Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.

Talk to our experts

Let’s Build the Right Formulation — Together

Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.

Talk to our experts

Let’s Build the Right Formulation — Together

Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.

Talk to our experts

Let’s Build the Right Formulation — Together

Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.

Talk to our experts

Let’s Build the Right Formulation — Together

What we work with

Enveloped DNA viruses

(HSV, HBV, EBV, MVA): fragile lipid envelopes prone to disruption; stabilization strategies protect integrity and infectivity.

Enveloped DNA viruses

(HSV, HBV, EBV, MVA): fragile lipid envelopes prone to disruption; stabilization strategies protect integrity and infectivity.

Enveloped RNA viruses

(VSV, Measles, Influenza): highly sensitive to pH and temperature shifts; stabilization prevents envelope degradation and RNA hydrolysis.

Enveloped RNA viruses

(VSV, Measles, Influenza): highly sensitive to pH and temperature shifts; stabilization prevents envelope degradation and RNA hydrolysis.

Virus-like particles (VLPs)

(HBsAg, HBcAg, mixed-particle vaccines): particle integrity and conformational stability critical for immunogenicity; challenging lyophilization and reconstitution profiles.

Virus-like particles (VLPs)

(HBsAg, HBcAg, mixed-particle vaccines): particle integrity and conformational stability critical for immunogenicity; challenging lyophilization and reconstitution profiles.

a

text for spacing

Best-in-class formulations for Ad5 viruses and viral vectors

Best-in-class formulations for Ad5 viruses and viral vectors

Case Study

Internal R&D project implementing an excipient preselection approach, enabling rational formulation development and the generation of best-in-class formulations for Ad5 viruses and viral vectors in liquid.

Case Study

Customer project (oncology) to stabilize human adenovirus in lyophilized form: Leukocare successfully stabilized an adenovirus with undisclosed insert during lyophilization and storage for at least 24 months. After lyophilization titer drop was < 0.3 log; total titer drop during lyophilization and storage was < 0.4 log.





Internal R&D project implementing an excipient preselection approach, enabling rational formulation development and the generation of best-in-class formulations for Ad5 viruses and viral vectors in liquid.





Best-in-class formulations for Ad5 viruses and viral vectors

Development of an influenza vaccine as dry powder

Case Studies

Stabilization of human adenovirus (ATMP)

Case Studies

Stabilization of human adenovirus (ATMP)

Case Study

R&D collaboration with Christian-Albrechts-University (Kiel, Germany): Development of an influenza vaccine as dry powder to increase stability, enable terminal sterilization, and to utilize alternative routes of administration.
Immune response in non-human primates was fully retained after spray-drying and irradiation with Leukocare formulation compared to non-irradiated original influenza vaccine.
Storage at ambient conditions (25°C and 60% relative humidity) did not show an influence on the antigen integrity and activity.


Immune response in macaques to influenza vaccine (HAI titer), PBS=negative control. *significantly different (p < 0.01) from group 2, 4 and 5 mean titers of groups 2, 4 and 5 were not significantly different from one another (bars represent the geometric mean titer for each group)

Development of an influenza vaccine as dry powder

Why high concentration matters

Why high concentration matters